Micofenolato De Mofetilo Aurovitas

Mycophenolate mofetil, the active ingredient in Micofenolato De Mofetilo Aurovitas, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ rejection, treat lupus nephritis, and reduce graft‑versus‑host disease risk in appropriate patients.

GNH USA supplies Micofenolato De Mofetilo Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate mofetil is used in several immunologically mediated conditions, primarily to suppress abnormal lymphocyte activity.

- Prevention of acute organ rejection: lowers the incidence of graft loss in kidney, heart, liver and other solid‑organ transplants. - Treatment of lupus nephritis: helps control renal inflammation and proteinuria in systemic lupus erythematosus. - Prevention of graft‑versus‑host disease: reduces the occurrence and severity of GVHD after hematopoietic stem cell transplantation.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cell count. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy: increased risk of post‑transplant lymphoproliferative disorder. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease of the central nervous system.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.

- Pregnancy: Category D – avoid use unless benefits outweigh risks. - Renal impairment: assess renal function and adjust dose as needed. - Hepatic impairment: monitor liver enzymes regularly. - Infection risk: screen for latent infections and vaccinate appropriately before treatment. - Live vaccines: contraindicated during therapy due to immunosuppression. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mycophenolate mofetil may interact with several concomitant medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole): increase mycophenolate exposure and toxicity. - Antacids containing magnesium or aluminum: reduce oral absorption of mycophenolate. - Azathioprine: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Mycophenolic acid formulations: concurrent use may increase adverse effects. - High‑dose steroids: may augment immunosuppressive effect. - Vaccines (inactivated): monitor immune response efficacy.